Low-Dose Testosterone in Women With Kidney Disease: A Step-by-Step Titration Guide

Why Kidney Function Changes Testosterone Pharmacology in Women

Kidney disease does not just affect drugs that are renally excreted. It changes how testosterone is absorbed, distributed, and metabolized in ways that matter for dose selection.

Testosterone itself is not primarily excreted by the kidneys. It is metabolized hepatically to androsterone and etiocholanolone glucuronides, which are then renally cleared. In women with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², these glucuronide conjugates accumulate, and endogenous androgen levels are already disrupted by uremia-driven suppression of the hypothalamic-pituitary-gonadal axis. This means a woman with CKD stage 4 may present with symptoms of androgen deficiency even when serum testosterone is within the formal "normal" range, because much of the measured hormone is bound to altered proteins and biologically inactive.

Sex hormone-binding globulin (SHBG) is frequently depressed in women with nephrotic-range proteinuria because SHBG is lost in the urine. Lower SHBG means a higher fraction of free testosterone for any given total testosterone dose, increasing both therapeutic effect and androgenic side-effect risk at doses that would be unremarkable in a woman with intact kidneys. Conversely, women with CKD stages 3 to 5 who are not nephrotic may have elevated SHBG due to chronic inflammation, reducing free testosterone and making them relatively resistant to standard doses.

The Anemia of CKD Complicates Safety Monitoring

Erythropoiesis stimulation is a known androgen effect. In a woman without kidney disease on low-dose testosterone, a rise in hemoglobin of 1 to 2 g/dL is rarely clinically significant. In a woman already receiving erythropoiesis-stimulating agents (ESAs) for anemia of CKD, even a modest testosterone-driven erythropoietic stimulus can push hematocrit above 52%, the threshold at which polycythemia risk rises meaningfully. Hematocrit should be checked at baseline and at every titration visit.

Dialysis Alters Transdermal Absorption

Women on hemodialysis have altered skin perfusion and hydration patterns that can affect transdermal drug absorption. No pharmacokinetic study has specifically measured transdermal testosterone absorption in women on dialysis; this is an evidence gap you deserve to know about. Clinicians managing women on hemodialysis should anticipate higher variability in serum levels and check labs mid-week between sessions rather than immediately post-dialysis.

What Low-Dose Testosterone Is Prescribed For in Women

Low-dose testosterone in women is used primarily for hypoactive sexual desire disorder (HSDD), the most common female sexual dysfunction, affecting approximately 10% of premenopausal and up to 40% of postmenopausal women in population surveys. Secondary uses include off-label management of fatigue, diminished well-being, and muscle mass preservation in women with established androgen deficiency.

The Global Consensus Position Statement on testosterone therapy for women, published jointly by The Menopause Society (formerly NAMS) and 11 other societies, supports testosterone use in postmenopausal women with HSDD at doses that achieve serum levels within the premenopausal physiological range, explicitly cautioning against supraphysiological dosing. No testosterone product is currently FDA-approved for use in women in the United States, so compounded transdermal preparations are the standard route of access.

Female-Relevant Conditions That Intersect With Renal Impairment

Several conditions that commonly co-occur with CKD in women are also relevant to testosterone prescribing decisions:

• PCOS: Women with PCOS already have elevated androgens. CKD in the context of PCOS requires confirming true androgen deficiency before prescribing, because the baseline may already be in the therapeutic range.
• Type 2 diabetes: Diabetic nephropathy is the leading cause of CKD in women. Insulin resistance independently lowers SHBG, increasing free testosterone fraction.
• Lupus nephritis: SLE, which affects women at a 9:1 ratio over men, is a significant cause of CKD in reproductive-age women. Testosterone use in active lupus is poorly studied; the immunomodulatory effects of androgens in SLE remain incompletely characterized.
• Osteoporosis: CKD-mineral bone disorder (CKD-MBD) and androgen deficiency both contribute to bone loss in women. Testosterone's modest anabolic bone effects may be a secondary benefit in this population, though it should not replace standard CKD-MBD management.

Standard Low-Dose Testosterone Titration in Women (Baseline Reference)

Before addressing renal impairment specifically, you need a clear picture of what standard titration looks like, so the modification makes sense.

The APHRODITE trial and the INTIMATE trials established that a 300 mcg/day testosterone patch produced meaningful improvement in satisfying sexual events in postmenopausal women, with serum total testosterone rising to a mean of approximately 57 ng/dL, well within the premenopausal physiological range. These trials used a fixed dose rather than a titration schedule, but real-world compounded prescribing typically titrates.

A standard compounded transdermal protocol in a woman without organ impairment:

| Phase | Dose | Duration Before Review | |---|---|---| | Initiation | 300 mcg/day (0.3 mg/day) cream or gel | 4 to 6 weeks | | First titration (if insufficient response) | 400 to 500 mcg/day | 6 weeks | | Maintenance ceiling | 500 mcg/day (to stay within physiological range) | Ongoing with 6-month labs |

Target serum total testosterone: upper quartile of the premenopausal reference range, typically 15 to 70 ng/dL by LC-MS/MS assay. Immunoassay-based testosterone measurements are unreliable at female-range concentrations; LC-MS/MS is the required method.

Modified Titration Protocol for Women With Renal Impairment

Women with CKD require three specific modifications: a lower starting dose, longer intervals between titration steps, and expanded lab monitoring.

The WomanRx Renal-Modified Testosterone Titration Framework for Women organizes dose steps by CKD stage:

CKD Stage 1 to 2 (eGFR >60 mL/min/1.73 m²)

Pharmacokinetic differences at this stage are modest. You can use the standard starting dose of 300 mcg/day but should extend the first review interval to 8 weeks and add a baseline hematocrit and mid-titration hematocrit check. SHBG should be measured at baseline to assess free testosterone fraction.

If nephrotic-range proteinuria is present (urine protein-to-creatinine ratio >3.5 g/g), treat as CKD stage 3 for dosing purposes because of the SHBG effect described above.

CKD Stage 3 (eGFR 30 to 59 mL/min/1.73 m²)

Start at 150 to 200 mcg/day. This is half the standard starting dose. The rationale: accumulation of androgenic glucuronide metabolites combined with SHBG variability makes serum level prediction unreliable at standard doses. Allow 10 to 12 weeks before the first dose adjustment. If serum total testosterone by LC-MS/MS is below 15 ng/dL and symptoms persist, increase by 100 mcg/day increments only.

CKD Stage 4 to 5 (eGFR <30 mL/min/1.73 m², not on dialysis)

Start at 100 to 150 mcg/day. Review at 12 weeks. Given the degree of HPG-axis suppression from uremia, some women will report symptomatic improvement at doses that produce serum testosterone levels still in the lower quartile of the premenopausal range, because even a small exogenous increment is meaningful when endogenous production is near zero. Do not escalate dose based on symptoms alone without confirming serum levels; the free testosterone fraction may be disproportionately elevated.

Women on Dialysis (Hemodialysis or Peritoneal)

Start at 100 mcg/day. Draw serum testosterone mid-week (Wednesday for a Monday/Wednesday/Friday HD schedule) and at least 24 hours after peritoneal dialysis exchange. Given the evidence gap in absorption data for this population, treat the first 16 weeks as purely exploratory and do not titrate upward until you have two consistent serum values.

| CKD Stage | Starting Dose | First Review | Max Increment | |---|---|---|---| | 1 to 2 (eGFR >60) | 300 mcg/day | 8 weeks | 150 mcg | | 3 (eGFR 30 to 59) | 150 to 200 mcg/day | 10 to 12 weeks | 100 mcg | | 4 to 5 (eGFR <30) | 100 to 150 mcg/day | 12 weeks | 100 mcg | | Dialysis | 100 mcg/day | 16 weeks | 50 to 100 mcg |

Monitoring Labs and Thresholds for Dose Adjustment or Discontinuation

Monitoring is more intensive in women with CKD than in the general population. Here is the minimum schedule:

At Baseline (Before Starting)

• Serum total testosterone (LC-MS/MS), free testosterone, SHBG
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel (CMP) including eGFR
• Urine protein-to-creatinine ratio if not already documented
• Lipid panel (testosterone has modest effects on HDL at higher doses)
• Blood pressure

At Each Titration Visit

• Serum total testosterone (LC-MS/MS) drawn in the morning, at least 4 hours after application
• Hematocrit (hold dose or reduce if hematocrit exceeds 52%, per Endocrine Society guidance on androgen therapy monitoring)
• Any new androgenic symptoms: acne, hirsutism (scored by modified Ferriman-Gallwey scale), scalp hair changes, voice deepening
• Blood pressure (testosterone can modestly increase blood pressure in susceptible women)
• eGFR (to detect CKD progression that would require further dose reduction)

At 6-Month Maintenance (Once Target Level Reached)

• All baseline labs repeated
• Patient-reported outcome: validated FSFI (Female Sexual Function Index) or DESIR questionnaire score to confirm ongoing therapeutic benefit

A meaningful symptom response is defined as a minimum 1.2-point improvement on the FSFI desire subscale sustained over two consecutive visits. If there is no response after reaching the upper dose for the CKD stage, discontinue rather than escalating beyond physiological range.

Life-Stage Considerations

Reproductive Years (Ages Roughly 18 to 45)

Premenopausal women with CKD and androgen deficiency symptoms present a particular diagnostic challenge. Serum testosterone fluctuates by up to 30% across the menstrual cycle, peaking in the late follicular phase around day 12 to 14. Labs should always be drawn in the early follicular phase (days 2 to 5 of the cycle) to avoid overestimating endogenous production and thereby starting at too low a dose or missing true deficiency. CKD in reproductive-age women is frequently caused by lupus nephritis, IgA nephropathy, or diabetic nephropathy from early-onset type 2 diabetes. All of these add complexity to the hormonal picture.

Women in this age group are also most likely to be considering pregnancy. Testosterone is absolutely contraindicated in pregnancy. See the dedicated section below.

Perimenopause (Typically Ages 44 to 54)

Perimenopause independently lowers testosterone production as ovarian function becomes erratic. A woman entering perimenopause with CKD stage 3 may experience a sharper symptomatic decline than her peers with intact kidneys, because the CKD-related HPG suppression compounds the ovarian decline. The SWAN (Study of Women's Health Across the Nation) documented a significant decline in free testosterone across the menopausal transition. Perimenopause-stage women with CKD are likely among the most androgen-depleted group encountered in clinical practice.

Menstrual irregularity in perimenopause makes cycle-timed labs impractical. Draw labs at any consistent time of day, document cycle day if known, and rely more heavily on the free testosterone fraction and symptom scores than on total testosterone alone.

Postmenopause

This is the population with the most clinical trial data, though even here, CKD was an exclusion criterion in the major testosterone RCTs. Postmenopausal women have naturally lower testosterone than premenopausal women, so the absolute dose required to reach therapeutic free testosterone levels is lower. CKD compounds this by suppressing HPG and altering SHBG. The renal-modified protocol above applies directly, and most postmenopausal women with CKD will find their maintenance dose is at or below the CKD-stage-specific starting dose.

Pregnancy, Lactation, and Contraception

Testosterone is contraindicated in pregnancy. This is not a precaution. It is a contraindication.

Exogenous testosterone exposure in a pregnant woman carrying a female fetus causes virilization of the external genitalia, a permanent structural effect that cannot be reversed after birth. The sensitive window is the first trimester, when fetal sex differentiation occurs, but androgen exposure at any stage of pregnancy carries risk.

Testosterone has no FDA-approved indication in women, and therefore no formal pregnancy category under the old letter system. Under the current FDA labeling framework, the labeling for testosterone products across all forms consistently states that testosterone is contraindicated in pregnant women and that androgenic steroids are known teratogenic agents in animals and in human case reports.

What this means for you if you have CKD and are premenopausal:

Women with CKD stages 1 to 3 can and do conceive, though fertility may be reduced. If you are using low-dose testosterone for HSDD or androgen deficiency and you have any possibility of pregnancy, you must use reliable contraception throughout treatment. The recommended methods are:

• An intrauterine device (copper or hormonal)
• A progestin implant (note: hormonal IUDs and implants are generally safe in CKD and do not worsen proteinuria)
• Combined hormonal contraception (requires individual assessment in CKD, especially if blood pressure is elevated)

Stop testosterone immediately if pregnancy is confirmed or suspected. There are no data showing that brief first-trimester exposure from low-dose transdermal testosterone before pregnancy recognition invariably causes harm, but the precautionary principle applies, and your clinician should be notified the same day.

Lactation: Testosterone passes into breast milk. The extent of infant exposure from maternal transdermal low-dose testosterone is not quantified in controlled studies. Given the potential for androgenic effects in a nursing infant, testosterone use is not recommended during breastfeeding. If HSDD or androgen deficiency symptoms are severe in the postpartum period, non-hormonal options should be tried first, and testosterone considered only after weaning, with shared decision-making documented.

Who This Protocol Is Right For (and Who Should Not Use It)

Likely to Benefit

• Postmenopausal women with CKD stages 1 to 4 and confirmed HSDD (FSFI desire subscale <3.3) who have not responded to relationship counseling or non-hormonal approaches
• Perimenopausal women with CKD and androgen deficiency confirmed by LC-MS/MS on appropriately timed labs
• Women on dialysis with significant quality-of-life impact from low desire or severe androgen-deficiency fatigue, who have been counseled about the evidence gap

Not Appropriate

• Any woman who is pregnant, trying to conceive, or not using reliable contraception
• Women with CKD and hematocrit already above 48% at baseline (particularly those on ESAs)
• Women with active androgenic alopecia or significant hirsutism (testosterone will worsen both)
• Women with hormone-sensitive cancer, including breast or endometrial cancer (the 2023 Endocrine Society Clinical Practice Guideline on menopause notes the absence of long-term safety data in cancer survivors)
• Women with PCOS and CKD whose baseline testosterone is already in the mid-to-upper premenopausal range

The Evidence Gap You Should Know About

No randomized controlled trial of low-dose testosterone in women has enrolled patients with CKD as a primary population. The APHRODITE trial excluded women with significant renal impairment. The INTIMATE SM1 and SM2 trials did not report CKD subgroup analyses. The titration framework above is built from three sources: the pharmacokinetic behavior of androgenic metabolites in renal impairment studied in male populations and extrapolated to women, the general female testosterone trial data, and renal dosing principles for protein-bound drugs.

Women have been historically under-represented in pharmacokinetic studies. Women with CKD have been under-represented even within that already-thin group. The dosing recommendations in this article are clinically reasoned, not trial-validated for this specific population. Your prescriber should document this evidence gap in the shared decision-making conversation, and you should be re-evaluated more frequently than a woman without kidney disease.

Practical Application Notes From the WomanRx Clinical Team

Application site rotation matters more in CKD. Edema is common in CKD stages 3 to 5, and applying testosterone cream to edematous tissue on the inner thigh or abdomen may produce erratic absorption. The inner forearm or upper arm is preferred. Rotate sites daily and apply to the thinnest, least edematous area available.

Compounded testosterone preparations vary in vehicle. A hydroalcoholic gel may absorb differently than a cream in a woman with very dry skin from uremia. If serum levels are consistently lower than expected for the dose, ask your compounding pharmacy about switching vehicles before escalating dose.

Drug interactions specific to women with CKD: Corticosteroids used for lupus nephritis or transplant immunosuppression can independently suppress testosterone production and alter SHBG. Tacrolimus and cyclosporine have not been shown to directly interact with testosterone pharmacokinetics in women, but cyclosporine is a CYP3A4 inhibitor and may modestly slow hepatic testosterone metabolism, potentially increasing effective exposure.

If your eGFR declines by more than 15 mL/min/1.73 m² between visits, reduce testosterone dose by one step on the table above and re-check labs in 8 weeks. Treat CKD progression as a reason to reassess the dose actively, not to wait until symptoms worsen.

Your target is not the highest dose that avoids obvious side effects. It is the lowest dose that produces a confirmed, sustained improvement in the symptom that brought you to treatment. For most women with CKD in the APHRODITE-extrapolated range, that dose is below 400 mcg/day.